Olfactory loss in people with cystic fibrosis: Community perceptions and impact

被引:4
作者
Miller, Jessa E. [1 ]
Liu, Christine M. [2 ]
Zemanick, Edith T. [3 ]
Woods, Jason C. [4 ]
Goss, Christopher H. [5 ]
Taylor-Cousar, Jennifer L. [6 ,7 ]
Beswick, Daniel M. [1 ]
机构
[1] Univ Calif Los Angeles, Dept Otolaryngol Head & Neck Surg, Los Angeles, CA USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA
[3] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA
[4] Cincinnati Childrens Hosp, Med Ctr, Dept Radiol, Cincinnati, OH USA
[5] Univ Washington, Dept Pulm Med, Seattle, WA USA
[6] Natl Jewish Hlth, Dept Med & Pediat, Denver, CO USA
[7] Univ Colorado, Dept Internal Med & Pediat, Anschutz Med Campus, Aurora, CO USA
基金
美国国家卫生研究院;
关键词
Olfactory dysfunction; Cystic fibrosis; Olfaction; Quality of life; Smell;
D O I
10.1016/j.jcf.2023.11.006
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Olfactory dysfunction (OD) is prevalent in people with cystic fibrosis (PwCF) and can negatively impact quality-of-life (QOL). This study evaluated perceptions of OD, investigated how OD impacts QOL, and assessed willingness to participate in OD research among the CF community. Methods: A 21-question survey was distributed through the CF Foundation's Community Voice program in 2023. The survey included questions on olfaction and interest in research. The Brief Questionnaire of Olfactory Disorders (BQOD), a validated person-reported outcome measure to assess QOL, was included. Results: Seventy-six responses were received. Overall, 91% (69/76) reported olfactory problems. Mean BQOD score was 5.0 (standard deviation=4.8), indicating olfactory QOL impairment was present. Ninety-five percent (72/76) reported research on OD is worthwhile and were willing to participate in research. Conclusion: Among PwCF, OD and olfactory-specific QOL impairments are prevalent. There is strong interest and willingness to participate in OD research among the CF community.
引用
收藏
页码:1195 / 1198
页数:4
相关论文
共 20 条
[1]   Olfaction before and after initiation of elexacaftor-tezacaftor-ivacaftor in a cystic fibrosis cohort [J].
Bacon, Daniel R. ;
Stapleton, Amanda ;
Goralski, Jennifer L. ;
Ebert, Charles S., Jr. ;
Thorp, Brian D. ;
Nouraie, Mehdi ;
Shaffer, Amber D. ;
Senior, Brent A. ;
Lee, Stella E. ;
Zemke, Anna C. ;
Kimple, Adam J. .
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2022, 12 (02) :223-226
[2]   Objective and patient-based measures of chronic rhinosinusitis in people with cystic fibrosis treated with highly effective modulator therapy [J].
Beswick, Daniel M. ;
Humphries, Stephen M. ;
Miller, Jessa E. ;
Balkissoon, Connor D. ;
Khatiwada, Aastha ;
Vladar, Eszter K. ;
Ramakrishnan, Vijay R. ;
Lynch, David A. ;
Taylor-Cousar, Jennifer L. .
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2022, 12 (11) :1435-1438
[3]   Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del [J].
Beswick, Daniel M. ;
Humphries, Stephen M. ;
Balkissoon, Connor D. ;
Strand, Matthew ;
Miller, Jessa E. ;
Khatiwada, Aastha ;
Vladar, Eszter K. ;
Lynch, David A. ;
Taylor-Cousar, Jennifer L. .
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2022, 12 (07) :963-966
[4]   Olfactory dysfunction in cystic fibrosis: Impact of CFTR modulator therapy [J].
Beswick, Daniel M. ;
Humphries, Stephen M. ;
Balkissoon, Connor D. ;
Strand, Matthew ;
Vladar, Eszter K. ;
Ramakrishnan, Vijay R. ;
Taylor-Cousar, Jennifer L. .
JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (02) :E141-E147
[5]   Improvement in sinonasal quality-of-life indicators for pediatric patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor [J].
Castellanos, Carlos X. ;
Osterbauer, Beth ;
Hasday, Steven ;
Keens, Thomas G. ;
Koempel, Jeffrey ;
Ference, Elisabeth H. .
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2023, 13 (01) :72-75
[6]  
cff, Community Voice
[7]  
Cystic Fibrosis Foundation, 2021, Cystic Fibrosis Foundation Patient Registry: 2021 annual data report
[8]   Cystic Fibrosis: The Sense of Smell [J].
Di Lullo, Antonella M. ;
Iacotucci, Paola ;
Comegna, Marika ;
Amato, Felice ;
Dolce, Pasquale ;
Castaldo, Giuseppe ;
Cantone, Elena ;
Carnovale, Vincenzo ;
Iengo, Maurizio .
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, 2020, 34 (01) :35-42
[9]   Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis [J].
DiMango, Emily ;
Overdevest, Jonathan ;
Keating, Claire ;
Francis, Sarah Fracasso ;
Dansky, David ;
Gudis, David .
JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (03) :460-463
[10]   Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial [J].
Heijerman, Harry G. M. ;
McKone, Edward F. ;
Downey, Damian G. ;
Van Braeckel, Eva ;
Rowe, Steven M. ;
Tullis, Elizabeth ;
Mall, Marcus A. ;
Welter, John J. ;
Ramsey, Bonnie W. ;
Mckee, Charlotte M. ;
Marigowda, Gautham ;
Moskowitz, Samuel M. ;
Waltz, David ;
Sosnay, Patrick R. ;
Simard, Christopher ;
Ahluwalia, Neil ;
Xuan, Fengjuan ;
Zhang, Yaohua ;
Taylor-Cousar, Jennifer L. ;
Mccoy, Karen S. .
LANCET, 2019, 394 (10212) :1940-1948